|Videos|July 11, 2017

Dr. Shah on CAR T-cell Therapy's Effectiveness in ALL

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, explains why chimeric antigen receptor (CAR) T-cell therapy has shown the most progress in acute lymphoblastic leukemia (ALL).

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Dr. Shah on CAR T-cell Therapy's Effectiveness in ALL

Related Content

Thomas Crawford, MD, on High-Dose Nusinersen and the Future of SMA Treatment

Srikanth Muppidi, MD, on Evaluating Miv-Cel in Myasthenia Gravis

Amanda Piquet, MD, FAAN, on Assessing Miv-Cel in Stiff Person Syndrome

Angela Lek, PhD, on the FDA's Approval of High-Dose Nusinersen in SMA

ImmunoLogic, Episode 9: "Rewiring Immunotherapy for High-Risk Neuroblastoma" With Kristopher R. Bosse, MD

Latest CME

Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

Oncology Town Hall: Insights Reshaping How We Treat MPNs From the 2026 Summer Oncology Meetings

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

A Community-Based Roadmap to CAR-T Therapy: Optimizing Delivery and Outcomes

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

Kentucky Society of Clinical Oncology

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Imaging Matters: Decoding PSMA PET for Better Decision-Making

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

SimulatEd™: Partnering for Precision – A Framework for Personalized Care Planning in Acute Lymphoblastic Leukemia

9th Annual School of Nursing Oncology™

Cases and Conversations™: Optimizing Outcomes in PV and ET—Evolving Standards, Symptom Management, and Therapeutic Innovation

Community Practice Connections™ Next Generation Therapies in AML: Menin Inhibitors, IDH1/2, Combinations, and Beyond!

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Oncology Town Hall: Shaping the Future of ALL Treatment Through Innovation in T-Cell Therapies